title: The administration sequence of propofol and remifentanil does not affect the ED50 and ED95 of rocuronium in rapid sequence induction of anesthesia: a double-blind randomized controlled trial.
abstract: The topic of drug administration sequence in rapid sequence induction (RSI) is still an object of interest in terms of rocuronium effectiveness. The aim of this prospective, randomized trial was to evaluate the effect of administration sequence of propofol and remifentanil on ED50 and ED95 of rocuronium in a RSI model.
  
  
  
  Eighty-four patients were randomized into Group Remifentanil (Group R, n = 43), where induction of general anesthesia started with remifentanil (2 µg/kg) and followed by propofol (2 mg/kg) and rocuronium administrations; and Group Propofol (Group P, n = 41), where induction of general anesthesia started with propofol and followed by remifentanil and rocuronium. First patients in each group were paralyzed by 0.8 mg/kg rocuronium. In case of acceptable intubation as evaluated according to the criteria described by Viby-Mogensen et al, rocuronium dose was decreased by 0.1 mg/kg for the next patient; otherwise, rocuronium dose was increased by 0.1 mg/kg. After three crossover points, increments or decrements in rocuronium dosage were set to 0.05 mg/kg. The process was repeated until a total of ten crossover points were obtained.
  
  
  
  The ED50 and ED95 doses of rocuronium were similar in Group R (0.182 mg/kg, and 0.244 mg/kg, respectively) and Group P (0.121 mg/kg, and 0.243 mg/kg, respectively) according to 95% CI of the estimates. There was no statistically significant difference in terms of clinically acceptable intubation conditions between the two groups (56.1% in Group R vs. 59% in Group P, p = 0.795).
  
  
  
  The choice of administration sequence of propofol and remifentanil does not have an impact on estimated ED50 and ED95 of rocuronium in providing acceptable intubation conditions in the RSI technique.
authors.affiliation: Department of Anesthesiology and Intensive Care Medicine, Ankara University Faculty of Medicine, Ankara, Turkey. ozcelikmenekse@yahoo.com.
authors.forename: M
authors.initials: M
authors.lastname: Ozcelik
authors.forename: C
authors.initials: C
authors.lastname: Guclu
authors.forename: O
authors.initials: O
authors.lastname: Bermede
authors.forename: V
authors.initials: V
authors.lastname: Baytas
authors.forename: N
authors.initials: N
authors.lastname: Altay
authors.forename: M A
authors.initials: MA
authors.lastname: Karahan
authors.forename: B
authors.initials: B
authors.lastname: Erdogan
authors.forename: O
authors.initials: O
authors.lastname: Can
mesh_terms: D000732:Androstanols / Q000627:therapeutic use*; D018686:Anesthetics, Intravenous / Q000008:administration & dosage*; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D007442:Intubation, Intratracheal; D003473:Neuromuscular Nondepolarizing Agents; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D015742:Propofol / Q000008:administration & dosage*; D011446:Prospective Studies; D000077208:Remifentanil; D000077123:Rocuronium
chemical_list: D000732:Androstanols; D018686:Anesthetics, Intravenous; D003473:Neuromuscular Nondepolarizing Agents; D010880:Piperidines; D000077208:Remifentanil; D000077123:Rocuronium; D015742:Propofol